• DOT1L Inhibition in Renal Fibrosis

  2026-08-26

  The reference study identifies DOT1L-dependent H3K79 dimethylation as a regulator of renal fibroblast activation and epithelial–mesenchymal transition after kidney injury. Using EPZ5676, DOT1L silencing, and a unilateral ureteral obstruction model, the authors connect epigenetic signaling with profibrotic pathways and provide a framework for evaluating DOT1L as a renal fibrosis target.

• FK866 (APO866): NAMPT Inhibition in Cancer

  2026-08-26

  FK866, also called APO866, is a non-competitive NAMPT inhibitor that depletes intracellular NAD and ATP. Its strongest research rationale is in hematologic cancer research, including acute myeloid leukemia models, where it produces selective cytotoxicity and caspase-independent cell death.

• Human iPSC Intestinal Organoids for Pharmacokinetics

  2026-08-26

  Saito and colleagues established a direct three-dimensional culture strategy for generating expandable intestinal organoids from human induced pluripotent stem cells. The organoids could be propagated, cryopreserved, and converted into intestinal epithelial monolayers with enterocyte CYP and transporter activities, creating a practical human model for early pharmacokinetic studies.

• WDR36, Glycolysis, and Human Trophectoderm Fate

  2026-08-25

  An et al. show that WDR36 supports human blastoid formation and trophectoderm commitment by maintaining glycolytic metabolism. By combining mouse embryo experiments, human pluripotent stem cell-derived blastoids, transcriptomics, targeted metabolomics, and LDHA interaction analysis, the study connects a developmental regulator with metabolic control of early lineage specification.

• CPI-613: From Mitochondrial Flux to Assay Logic

  2026-08-24

  CPI-613 links mitochondrial carbon flux with interpretable cancer-cell death assays. This guide integrates PDH biology, PDHA1–cuproptosis signaling, and practical workflows for tumor cell metabolism studies without overstating translational evidence.

• Making Apoptosis Visible in Renal Amyloidosis Research

  2026-08-24

  A translational framework for using TUNEL-based DNA fragmentation readouts to strengthen mechanistic studies of renal amyloidosis, natural-product intervention, and programmed cell death. The article explains how the TUNEL Apoptosis Detection Kit (DAB) can connect tissue morphology with molecular evidence while preserving appropriate controls and interpretive limits.

• NS1, DNMT1, and HBoV1 RNA Processing

  2026-08-23

  A 2024 PLOS Pathogens study identifies DNMT1-dependent DNA methylation as a key regulator of human bocavirus 1 replication and RNA processing. The work shows that HBoV1 NS1 uses ubiquitin-proteasome-mediated DNMT1 degradation to shift the infection from efficient viral DNA synthesis toward productive viral RNA processing and protein expression.

• SCH772984 HCl: ERK1/2 Assay Guide

  2026-08-22

  A scenario-based guide to using SCH772984 HCl (SKU B5866) for ERK1/2 pathway interrogation, cell proliferation studies, and cytotoxicity assay interpretation. It covers concentration selection, solvent handling, orthogonal readouts, stem-cell research limitations, and practical product-selection criteria.

• Honokiol: From Mechanism to Translational Strategy

  2026-08-21

  Honokiol offers translational researchers a mechanistically rich way to connect NF-κB signaling, oxidative stress, inflammation, tumor biology, and assay interpretation. This article moves beyond a conventional product overview by integrating compound handling with orthogonal viability, cell-death, and pathway readouts informed by the Schwartz dissertation.

• Dabigatran etexilate: Assay Workflows

  2026-08-20

  Build a translational coagulation workflow around Dabigatran etexilate, from thrombin target engagement to plasma clotting and platelet responses. The guide emphasizes prodrug-aware assay design, practical controls, and troubleshooting for atrial fibrillation and broader anticoagulant research.

• ST3GAL1 Sialylation Drives F. nucleatum Adhesion

  2026-08-20

  The reference study identifies ST3GAL1-dependent host-cell sialylation as a determinant of Fusobacterium nucleatum adhesion to colorectal cancer cells. Its findings connect bacterial retention with an H3K27ac–ANGPTL4 program, providing a mechanistic framework for understanding how tumor glycosylation may support intratumoral microbial persistence.

• Norepinephrine Formulation Reporting in Critical Care

  2026-08-19

  The SCCM-ESICM joint task force identified clinically important variation in how norepinephrine is labeled and reported as a conjugated salt or active base. Its position paper argues that formulation identity and base-equivalent dose should be standardized to improve patient safety, trial enrollment, and cross-country interpretation of vasopressor datasets.

• BMS 599626 Dihydrochloride: EGFR/ErbB2 Inhibitor

  2026-08-19

  BMS 599626 dihydrochloride is an EGFR and ErbB2 inhibitor for preclinical studies of receptor phosphorylation, cancer cell proliferation inhibition, and xenograft tumor growth. Supplier-reported kinase potency and lung tumor xenograft findings support its use as a selective EGFR/HER2 signaling probe, not as a diagnostic or medical product.

• Dacarbazine: Bench Workflows for DNA Damage Studies

  2026-08-18

  Learn how to use Dacarbazine in reproducible cytotoxicity, proliferation, and DNA damage experiments rather than treating viability loss as a single endpoint. The workflow also shows how supportive-care evidence on palonosetron can inform translational study design without overstating what the reference proves.

• PAD4-IN-2 TFA: Tumor-Targeted PAD4 Inhibition

  2026-08-18

  PAD4-IN-2 TFA, also called Compound 5i TFA, is a meta-phenylboronic acid-modified PAD4 inhibitor designed for tumor-biased uptake. Preclinical studies link it to reduced histone H3 citrullination, neutrophil extracellular trap formation, tumor growth, and lung metastasis with favorable mouse safety markers.

8635 records 1/576 page Next 12345 下5页 Last page